ArticleEJHaem2026
Reticulated Platelets and an Optimal Model for Differentiating Thrombocytopenia Etiologies.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to investigate the clinical value of reticulated platelets (RtcPLT) percentage derived from an automated hematology analyzer in differentiating thrombocytopenia due to peripheral etiology from decreased bone marrow production (BME). In addition, a secondary objective was to establish specific reference intervals for RtcPLT and to propose an optimal diagnostic model. Methods: We conducted a descriptive cross-sectional study of 375 subjects, including 84 healthy controls and 291 thrombocytopenic patients. The healthy individuals were utilized to establish the RtcPLT reference range. The patient cohort was classified into PE and BME groups based on the results of bone marrow aspiration and biopsy (BMAB). RtcPLT was measured using the optical fluorescence method on the ADVIA 2120i platform. Diagnostic accuracy was evaluated using receiver operating characteristic (ROC) analysis and Bayesian model averaging (BMA) to propose the optimal model. Results: The median RtcPLT in the BME group (2.28%) was significantly lower than that of the PE group (8.27%, Conclusion: The RtcPLT index measured in this study is a robust, rapid, and automated biomarker for assessing thrombopoietic activity. Furthermore, the optimal model we suggested provides near-perfect diagnostic accuracy, serving as an expeditious and cost-effective screening tool to reliably differentiate peripheral and bone marrow etiologies of thrombocytopenia. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.